

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 June 2021 (17.06.2021)



(10) International Publication Number
WO 2021/119538 A1

(51) International Patent Classification:

A61K 38/00 (2006.01) A61P 35/00 (2006.01)
A61K 39/00 (2006.01) A61P 37/04 (2006.01)
A61K 48/00 (2006.01) C07K 14/705 (2006.01)

(21) International Application Number:

PCT/US2020/064686

(22) International Filing Date:

11 December 2020 (11.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/946,896	11 December 2019 (11.12.2019)	US
16/826,708	23 March 2020 (23.03.2020)	US
63/003,617	01 April 2020 (01.04.2020)	US
63/014,068	22 April 2020 (22.04.2020)	US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US	16/826,708 (CIP)
Filed on	23 March 2020 (23.03.2020)

(71) Applicant: **MYELOID THERAPEUTICS, INC.**
[US/US]; 800 Boylston Street, Suite 2222, Boston, Massachusetts 02199 (US).


(72) Inventors: **GETTS, Daniel**; 800 Boylston Street, Suite 2222, Boston, Massachusetts 02199 (US). **WANG, Yuxiao**; 800 Boylston Street, Suite 2222, Boston, Massachusetts 02199 (US). **BISARIA, Namita**; 800 Boylston Street, Suite 2222, Boston, Massachusetts 02199 (US). **AUSTGEN, Kathryn**; 800 Boylston Street, Suite 2222, Boston, Massachusetts 02199 (US). **HARVEY, Caitlyn Anne Morrison**; 800 Boylston Street, Suite 2222, Boston, Massachusetts 02199 (US). **TAVARES, Patrick Mendes**; 800 Boylston Street, Suite 2222, Boston, Massachusetts 02199 (US).

(74) Agent: **GHOSH, Sanjukta**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

(54) Title: THERAPEUTIC CELL COMPOSITIONS AND METHODS FOR MANUFACTURE AND USES THEREOF

FIG. 2



(57) Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.

[Continued on next page]

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*